Anti-phospho-Filamin-A (Ser2152) Antibody, clone PS2

Filamin-A (UniProt P21333; also known as ABP-280, Actin binding protein 280, Alpha-filamin, Endothelial actin-binding protein, Filamin-1, FLN-A, Non-muscle filamin) is encoded by the FLNA (also known as ABP, CSBS, CVD1, FLN, FLN1, FMD, MNS, NHBP, OPD, OPD1, OPD2, XLVD, XMVD) gene (Gene ID 2316) in human. Filamin-A (FLN-A) is an actin-binding protein essential for cytoskeletal rearrangement and cell locomotion. Serine 2152 of FLN-A is a PKA phosphorylation target. FLN-A S2152 phosphorylation is essential for FLN-A-mediated recruitment of signaling proteins, adhesion molecules, and the vesicle-trafficking complex to the peripheral actin rim, so as to stabilize the cortical structure and epithelial membrane. Mutations in FLNA and ARFGEF2 genes cause periventricular heterotopia (PVH or PH), a congenital malformation of cortical development characterized by a reduced brain size and ectopic neuronal nodules along the ventricular neuroepithelium as a result of impaired initiation of neuronal migration. Suppression of either Arfgef2 or Mekk4 results in increased cellular FLN-A level and Ser2152 phosphorylation. In addition, Arfgef2 or Mekk4 deletion causes PVH in knockout mice.

~280 kDa observed

Epitope: Filamin repeat 20

KLH-conjugated linear peptide corresponding to the Filamin repeat 20 of human phospho-Filamin-A (Ser2152).

Research Category
Neuroscience

Research Sub Category
Developmental Neuroscience

This Anti-phospho-Filamin-A (Ser2152) Antibody, clone PS2 is validated for use in Western Blotting, Immunocytochemistry and Immunofluorescence for the detection of phospho-Filamin-A (Ser2152).

Western Blotting Analysis: A representative lot detected enhanced FLN-A Ser2152 phosphorylation in multiple tissue extracts (liver, heart, brain, and skin) from new born (P0) and E16.5 embryos of Arfgef2/Big2 knockout mice when compared with stage-matched tissue samples from wild-type mice (Zhang, J., et al. (2012). J. Neurosci. 32(36):12619-12629).
Western Blotting Analysis: A representative lot detected cellular FLN-A pSer2152 phosphorylation induction upon serum, forskolin, or EphB2-Fc addition to serum-starved CHP100 human neuroblastoma cells (Zhang, J. et al. (2013). J. Neurosci. 33(40):15735-15746).
Immunocytochemistry Analysis: A representative lot detected cellular FLN-A pSer2152 phosphorylation induction in neuronal progenitors from frontal cortex of E13.5–E14.5 mouse embryos, CHP100 human neuroblastoma cells, and A7, but not FLN-A-deficient M2, human melanoma cells upon forskolin addition (Zhang, J. et al. (2013). J. Neurosci. 33(40):15735-15746).
Immunofluorescence Analysis: A representative lot detected FLN-A pSer2152 immunoreactivity extended to the proliferative zone (PZ) surface at the periventricular heterotopia (PVH) congenital malformation site in the forebrain (FB) of E17.5 MEKK-/- mouse embryos in addition to the FLN-A pSer2152 immunoreactivity in the intermediate zone (IZ) and cortical plate (CP) seen in both wild-type and MEKK-knockout embryos by fluorescent immunohistochemistry (Sarkisian, M.R., et al. (2006). Neuron. 52(5):789-801).

Ser2152 of human and murine Filamin-A isoform 1 (P21333-1 & Q8BTM8-1) corresponds to Ser2144 of human Filamin-A isoform 2 (P21333-2). Equivalent site is not present in murine spliced isoform 2.

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG2bκ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.

Evaluated by Western Blotting in mouse embryonic fibroblast lysate.

Western Blotting Analysis: A 1:125 dilution of this antibody detected Calyculin A-stimulated Filamin-A Ser2152 phosphorylation in mouse embryonic fibroblasts (MEFs).

Concentration: Please refer to lot specific datasheet.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.